Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Insulin Icodec in Renal Impairment
NCT03723785Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of insulin icodec in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin 287 concentration-time curve. Started Nov 2018; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03723785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723785.